For research use only. Not for therapeutic Use.
XZ739 (CAT: I015276) is a CRBN-dependent PROTAC BCL-XL degrader, exhibiting potent activity against various cancer cell lines. In MOLT-4 cells, XZ739 demonstrates a DC50 value of 2.5 nM after 16 hours of treatment, leading to the degradation of BCL-XL protein. XZ739 displays strong antiproliferative effects, reducing the viability of T-ALL MOLT-4, B-ALL RS4; 11, SCLC NCI-H146 cells, and platelets with IC50 values of 10.1, 41.8, 25.3, and 1217 nM, respectively, after 48 hours of treatment. The degradation of BCL-XL by XZ739 occurs rapidly within 2 hours, with over 96% degradation observed after 8 hours of treatment with 100 nM XZ739 in MOLT-4 cells. Furthermore, XZ739 induces cell death through caspase-mediated apoptosis.
| Catalog Number | I015276 |
| CAS Number | 2365172-19-4 |
| Molecular Formula | C₆₅H₇₆ClF₃N₈O₁₂S₃ |
| Purity | ≥95% |
| Target | Apoptosis |
| Reference | [1]. Xuan Zhang,et al. Discovery of PROTAC BCL-X L Degraders as Potent Anticancer Agents With Low On-Target Platelet Toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. |
